These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 18663817)

  • 21. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
    Singh MS; Francis PA; Michael M
    Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen.
    Ferraldeschi R; Howell SJ; Thompson AM; Newman WG
    J Clin Oncol; 2010 Oct; 28(29):e584-5; author reply e586. PubMed ID: 20823421
    [No Abstract]   [Full Text] [Related]  

  • 23. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer.
    Wegman P; Elingarami S; Carstensen J; Stål O; Nordenskjöld B; Wingren S
    Breast Cancer Res; 2007; 9(1):R7. PubMed ID: 17244352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in adjuvant hormonal therapy for postmenopausal women.
    Strasser-Weippl K; Goss PE
    J Clin Oncol; 2005 Mar; 23(8):1751-9. PubMed ID: 15755983
    [No Abstract]   [Full Text] [Related]  

  • 25. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis.
    Seruga B; Amir E
    Breast Cancer Res Treat; 2010 Aug; 122(3):609-17. PubMed ID: 20454926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP2D6 genotyping and the pharmacogenetics of tamoxifen.
    Flockhart D
    Clin Adv Hematol Oncol; 2008 Jul; 6(7):493-4. PubMed ID: 18654115
    [No Abstract]   [Full Text] [Related]  

  • 27. Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users.
    Dieudonné AS; Lambrechts D; Claes B; Vandorpe T; Wildiers H; Timmerman D; Billen J; Leunen K; Amant F; Berteloot P; Smeets A; Paridaens R; Weltens C; Van Limbergen E; Van den Bogaert W; Vergote I; Van Huffel S; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2009 Dec; 118(3):531-8. PubMed ID: 19597703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response.
    Kiyotani K; Mushiroda T; Hosono N; Tsunoda T; Kubo M; Aki F; Okazaki Y; Hirata K; Takatsuka Y; Okazaki M; Ohsumi S; Yamakawa T; Sasa M; Nakamura Y; Zembutsu H
    Pharmacogenet Genomics; 2010 Sep; 20(9):565-8. PubMed ID: 20574415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antiestrogenic agents for treatment of advanced breast cancers].
    Kimura M
    Nihon Rinsho; 2000 Apr; 58 Suppl():311-6. PubMed ID: 11026011
    [No Abstract]   [Full Text] [Related]  

  • 30. CYP2D6 variants and the prediction of tamoxifen response in randomized patients: author response.
    Wegman PP; Wingren S
    Breast Cancer Res; 2005 Mar; 7(6):E7. PubMed ID: 16280043
    [No Abstract]   [Full Text] [Related]  

  • 31. Adjuvant hormone therapy for breast cancer: alternatives to tamoxifen.
    Prescrire Int; 2005 Jun; 14(77):108-10. PubMed ID: 15984106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should CYP2D6 be genotyped when treating with tamoxifen?
    Del Re M; Rofi E; Citi V; Fidilio L; Danesi R
    Pharmacogenomics; 2017 Jun; 18(8):755-756. PubMed ID: 28593824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
    Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
    Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK; Nielsen DL; Lindberg H; Kamby C
    Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Should CYP2D6 be genotyped when treating with tamoxifen?
    Del Re M; Rofi E; Citi V; Fidilio L; Danesi R
    Pharmacogenomics; 2016 Dec; 17(18):1967-1969. PubMed ID: 27883289
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
    Higgins MJ; Rae JM; Flockhart DA; Hayes DF; Stearns V
    J Natl Compr Canc Netw; 2009 Feb; 7(2):203-13. PubMed ID: 19200418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetics of endocrine therapy for breast cancer.
    Higgins MJ; Stearns V
    Annu Rev Med; 2011; 62():281-93. PubMed ID: 21226615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment.
    Ramón y Cajal T; Altés A; Paré L; del Rio E; Alonso C; Barnadas A; Baiget M
    Breast Cancer Res Treat; 2010 Jan; 119(1):33-8. PubMed ID: 19189210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?
    Hayes DF; Stearns V; Rae J; Flockhart D;
    J Natl Cancer Inst; 2008 May; 100(9):610-3. PubMed ID: 18445818
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.